Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

GfK Healthcare's Roper Global Diabetes Program Launches New U.S. Diabetes Patient Market Study
GfK Healthcare"s Roper Global Diabetes Program, the definitive global perspective on diabetes, announced today the launch of its enhanced U.S. Diabetes Patient Market Study. Through a modular approach and with tailored reporting, the study offers health care and related companies in the diabetes category access to patient data and market trends from one of the largest surveys of people with diabetes, and the only one projectable to the U.S. population.
generic viagra online
UGA Grad Program Expands To Prepare Teachers To Work With Secondary Students With Autism
An innovative University of Georgia graduate program in special education that has prepared scores of Georgia teachers to work with elementary-age students with autism over the last several years has received a new 4-year, $793,000 federal grant to train teachers to work with similarly challenged secondary-age students.
plastic surgery before after
News of the day
Call For Public Debates On Future Uses Of Stem Cells Lead By Bioethicists
More than 40 scientists, bioethicists, lawyers and science journal editors are calling on their colleagues, policy makers and the public to begin developing guidelines for the research and reproductive use of stem cell-derived eggs and sperm, even though such use may be a decade or more away.
Public Health

Ancora Pharmaceuticals Awarded National Institute Of Health Grant For Continued Malaria Vaccine Research

With exciting pre-clinical results showing that its carbohydrate-based vaccine can combat cerebral malaria (CM), which causes inflammation of the brain, Ancora Pharmaceuticals has received another grant from the National Institute of Health (NIH) to research whether its vaccine candidate will also prevent severe malaria anemia (SMA). The $530,000 Phase I SBIR grant is the third NIH grant Ancora has received. In 2005, the pharmaceutical company was awarded a $3.3 million grant from NIH to develop their current cerebral malaria vaccine candidate. Scientific evidence indicates that severe malarial disease results from the downstream effects of a toxin generated by the malaria parasite. This toxin gives rise to the same clinical manifestations observed in both CM and SMA, leading to the possibility that Ancora"s first vaccine candidate could be successfully used for both. Malaria afflicts up to ten percent of the global population resulting in between two and three million deaths per year. Because of global warming, the World Health Organization (WHO) has predicted that 50 percent of the population will be at risk of this disease by 2010. This latest grant demonstrates NIH"s continued confidence in Ancora"s ability to create cost-effective vaccines utilizing carbohydrate synthesis. The company"s breakthrough method of producing synthetic carbohydrates allows for approaches to bacterial, parasitic, and viral infectious diseases previously unattainable. Ancora Pharmaceuticals is a private venture-backed biopharmaceutical company based in Medford, Massachusetts focused on developing immune system modulation therapeutics using synthetic carbohydrates. Ancora"s automated carbohydrate synthesizer is internationally recognized as the most advanced in the world. Synthetic carbohydrate therapeutics represents an untapped opportunity within the pharmaceutical industry to develop promising vaccines against some of today"s worst infectious diseases. Ancora Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009